



ctos[®]

THE NOVEL KIT INHIBITOR IDRX-42 SHOWS PROMISING ACTIVITY IN 2ND AND LATER-LINE GASTROINTESTINAL STROMAL TUMORS: RESULTS FROM A PHASE 1 STUDY (STRATEGIST 1)

Suzanne George¹, Michael Heinrich², Jonathan Trent³, César Serrano⁴, Sebastian Bauer⁵, Margaret von Mehren⁶, Neeta Somaiah⁷, Peter Reichardt⁸, George Demetri¹, Nick Lydon⁹, David Kerstein⁹, Jaap Verweij⁹, Vivek Kadambi⁹, Jessica Christo⁹, Sean Kim⁹, Debbie Johnson⁹, James Shao⁹, Patrick Schöffski¹⁰

Suzanne George, MD
Chief, Division of Sarcoma
Dana-Farber Cancer Institute
Boston, MA USA

2024
ANNUAL MEETING

1. Dana-Farber Cancer Institute – Sarcoma Center, Boston, Massachusetts, USA; 2. Oregon Health & Science University (OHSU), Portland, OR, USA; 3. University of Miami – Sylvester Comprehensive Cancer Center, Miami, Florida, USA; 4. Hospital Universitari Vall d'Hebron - Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain; 5. Universitaetsklinikum Essen - Westdeutsches Tumorzentrum (WTZ) (West German Cancer Center), Essen, North Rhine-Westphalia, Germany; 6. Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA; 7. MD Anderson Cancer Center, Houston, Texas, USA; 8. Helios Klinikum Berlin-Buch, Berlin, Germany; 9. IDRx, Plymouth, Massachusetts, USA; 10. University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium

IDRX-42: a KIT TKI designed to address unmet need in GIST

- *KIT* mutations drive most GIST, with resistance to TKIs due to diverse secondary mutations in the ATP-binding pocket and activation loop
- No approved TKI inhibits the full spectrum of these mutations¹
 - Response rates with 2nd line sunitinib, 3rd line regorafenib, and 4th line ripretinib are approximately 18%, 5%, and 9%, respectively ^{2,3,4}
- IDRX-42 is an investigational KIT TKI which has shown:
 - Superior *in vivo* activity vs standard TKIs in xenograft mouse models with exon 9, 11, 13 and 17 mutations^{5,6}
 - Selectivity over off-target kinases, sparing VEGFR-2 and FLT3⁵

FLT3, fms-like tyrosine kinase 3; TKI, tyrosine kinase inhibitor; VEGFR-2, vascular endothelial growth factor receptor 2; Sources: 1. Kelly CM et al. J Hematol Oncol. 2021;14(1):2; 2. Bauer et al. J Clin Oncol. 2022;40(34):3918-3928; 3. Demetri et al. Lancet. 2013;381(9863):295-302; 4. Blay et al. Lancet Oncol. 2020 (7):923-934.; 5. Blum A et al. J Med Chem. 2023;66(4):2386-2395; 6. De Sutter L et al. Clin Cancer Res. 2023;29(15):2859-2868

STRATEGIST 1: Study design

Key Eligibility Criteria


- Metastatic and/or unresectable GIST
- Pathogenic mutations in *KIT* or non-exon 18 *PDGFRA*
- Progression on imatinib (phase 1)
- ECOG PS 0-1

Key Endpoints

- Safety/tolerability[§]
- PK
- Anti-tumor activity (investigator-assessed)[†]

Phase 1 Dose Escalation (3+3 Design)^{††}

NCT05489237



Phase 1b Cohorts at RP1bD(s)[‡]

1st Line

2nd Line

≥3rd Line with approved TKIs

≥3rd Line with investigational TKIs^{‡‡}

- As of 30 September 2024, 89 patients were enrolled in the Phase 1 portion at doses of 120 mg – 1200 mg, and are the focus of this update
- Phase 1b was initiated in May 2024 at a Recommended Phase 1b Dose (RP1bD) of 300 mg QD (tablet)

[§] Per NCI CTCAE version 5.0; [†] According to modified Response Evaluation in Solid Tumors (mRECIST) v1.1 (Demetri et al. Lancet. 2013;381(9863):295-302); ^{††} Dose escalation performed with IDRX-42 capsules, administered in 28-day cycles. Additionally, 3 cohorts enrolled with IDRX-42 tablets at 200 mg QD, 300 mg QD and 600 mg QD. Enrollment beyond 3+3 included backfill and dose confirmation patients; [‡] RP1bD: Recommended Phase 1b dose; 1-2 dose levels from the Phase 1 portion may be evaluated in Phase 1b; ^{‡‡} Prior bezuclastinib, NB003, or THE-630; BID, twice daily; DLT, dose limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group Performance Status; PK, pharmacokinetics; PDGFRA, platelet-derived growth factor receptor alpha; QD, once daily; RP1bD(s), TKIs, tyrosine kinase inhibitor

STRATEGIST 1: Patient and tumor characteristics

	All Patients N=89
Median age, years	59 (32-78)
Male, n (%)	57 (64)
Median time since diagnosis of unresectable/metastatic GIST, years	4.5
Median lines of prior systemic therapy (range) †	4 (1-8)
Prior therapy: 1 / 2 / ≥3 lines, n (%)	15 (17) / 10 (11) / 64 (72)
≥3 lines without ripretinib, n (%)	25 (28)
<i>KIT</i> mutation status §, n (%)	
<i>By local assessment or central baseline ctDNA analysis</i>	
Any <i>KIT</i> mutation	89 (100)
Any Exon 9	25 (28)
Any Exon 11	63 (71)


As of 30 September 2024, 63% of patients (56/89) remain on IDRX-42^{††}, with a median duration of treatment of 6.6 mo (range: 0.2-26)

† Imatinib administered in both the (neo)adjuvant setting and then first-line advanced setting is counted as 1 prior line; § 7/89 patients did not have a mutation reported in either exon 9 or 11 (2 patients each had a mutation in exon 8 and exon 13+17 and 1 patient had a mutation in exon 13 alone and 2 patients had a mutation in exon 17 alone) and 6/89 patients had a mutation reported in both exons 9 and 11; †† 28 patients discontinued for radiographic PD, 2 for clinical PD, 2 for adverse events, 1 for death (pneumonia, not related); ctDNA, circulating tumor deoxyribonucleic acid; PD, Data cutoff date: 30 September 2024

STRATEGIST 1: Promising anti-tumor activity in 2nd and later-line GIST


Objective Response Rate (ORR) [†] , n/N (%)	2 nd Line	3 rd Line	≥4 th Line No Prior Ripretinib	All Patients
All Doses	8/15 (53)	2/10 (20)	9/25 (36)	25/87 (29) ^{††}
400 mg capsule/300 mg tablet (RP1bD) [#]	6/13 (46)	2/4 (50)	2/10 (20)	10/38 (26)

Best Change in Tumor Target Lesions per mRECIST



[†] In the efficacy evaluable population, defined as all patients with at least one postbaseline disease assessment or prior clinical progression or death. Disease assessments according to mRECIST (modified RECIST v1.1; Demetri et al. Lancet. 2013;381(9863):295-302) performed at baseline, 4 weeks, 8 weeks and every 8 weeks thereafter; ^{††} Responses (n=25) includes 1 confirmed CR, 22 confirmed PR, and 2 PRs awaiting confirmation; [#] One patient each in the 600 and 800 mg cohorts had dose reduction to 400 mg early in Cycle 1 (Day 2 and 14, respectively) and are analyzed as effectively treated at 400 mg; [‡] As detected by local assessment or central baseline ctDNA analysis; Based on similar steady-state plasma exposures, data from the following dose/formulation pairs are analyzed together in this presentation: 200 mg tablet/240 mg capsule, 300 mg tablet/400 mg capsule, and 600 mg tablet/600 mg capsule; QD, once daily; RP1bD, Recommended Phase 1b Dose;; SLD, Sum Lesion Diameter; Data cutoff date: 30 September 2024

STRATEGIST 1: Duration of treatment and response in 2nd line patients




- Median duration of treatment: 8.7 months (range: 4.8-25.8)
- PFS (95% CI) at 6 months: 85% (51%-96%)
- Median PFS not estimable


†As detected by local assessment or central baseline ctDNA analysis; # One patient in the 800 mg dose cohort had dose reduction to 400 mg early in Cycle 1 (Day 14) and is analyzed as effectively treated at 400 mg; ^A Patient with *KIT* T670I mutation (exon 14) initially detected in ctDNA on C1D15. In preclinical studies, IDRX-42 had lower potency against T670I-containing variants compared to resistance mutations in exons 13 and 17; ^B Patient had PD after 30 days of dose interruption due to management of small bowel obstruction; ^C Patient with T670I mutation based on local assessment at baseline. This patient had a solitary hepatic lesion present at study entry which was subsequently completely resected on Study Day 88, with efficacy information censored thereafter in the analysis; PFS, progression-free survival (Kaplan-Meier estimate); PR, partial response; RP1bD, Recommended Phase 1b Dose; Data cutoff date: 30 September 2024

STRATEGIST 1: Durable clinical activity in heavily pretreated patients

Duration of Treatment and Response ≥3rd Line Patients



Progression-Free Survival, ≥3rd Line Patients




	Progression-Free Survival (PFS)			
	3 rd Line		≥4 th Line No Prior Ripretinib	
	N	Median PFS, months (95%CI)	N	Median PFS, months (95%CI)
All Doses	10	12.9 (0.8, NE)	25	9.2 (3.7, NE)
400 mg capsule/ 300 mg tablet (RP1bD)#	4	NE (1.9, NE)	10	11.0 (0.6, NE)

One patient in the 600 mg cohort had dose reduction to 400 mg early in Cycle 1 (Day 2) and is analyzed as effectively treated at 400 mg; NE, not estimable; PFS, progression-free survival (Kaplan-Meier estimate); RP1bD, Recommended Phase 1b Dose; Data cutoff date: 30 September 2024

STRATEGIST 1: Responses observed across *KIT* mutation subsets

ORR[†] by *KIT* Mutation According to Baseline Central ctDNA Analysis



[†] Confirmed responses and responses awaiting confirmation in the efficacy evaluable population (all lines of therapy) according to mRECIST (modified RECIST v1.1; Demetri et al. Lancet. 2013;381(9863):295-302); ctDNA, circulating tumor DNA;; ORR, objective response rate; Data cutoff date: 30 September 2024

STRATEGIST 1: IDRX-42 Favorable safety and tolerability profile

- Recommended Phase 1b Dose (RP1bD) yielded fewer dose reductions and Grade 3-4 TRAE (compared to higher doses)
- Mean relative dose intensity >90% at RP1bD for all completed cycles

Treatment-Related AEs (TRAE) and Dose Modifications

	400 mg capsule/300 mg tablet (RP1bD) N=36 [#]			All Patients N=89		
	Highest CTCAE Grade [†]					
	1	2	3-4 ^{††}	1	2	3-4 ^{††}
Any TRAE, n (%)	16 (44)	16 (44)	3 (8) [§]	27 (30)	34 (38)	21 (24)
TRAE in ≥15% Patients Overall						
Diarrhea	20 (56)	3 (8)		43 (48)	14 (16)	3 (3)
Nausea	17 (47)	4 (11)		37 (42)	9 (10)	3 (3)
Dysgeusia	12 (33)	2 (6)		24 (27)	6 (7)	
Fatigue	7 (19)	4 (11)		17 (19)	10 (11)	2 (2)
Decreased appetite	5 (14)			19 (21)	8 (9)	1 (1)
Vomiting	10 (28)	2 (6)		19 (21)	5 (6)	3 (3)
Anemia	2 (6)	5 (14)		7 (8)	11 (12)	6 (7)
Gastroesophageal reflux disease	7 (19)	3 (8)		15 (17)	5 (6)	
Periorbital edema	5 (14)			16 (18)		
Peripheral edema	2 (6)	1 (3)		13 (15)	2 (2)	
Neutrophil count decreased	2 (6)	4 (11)		3 (3)	7 (8)	4 (5)

Dose Modifications

TRAE leading to dose reduction [‡] , n (%)	3 (8)	15 (17)
TRAE leading to dose interruption, n (%)	6 (17)	21 (24)
TRAE leading to discontinuation, n (%)	0	2 (2)

[#] All patients who initiated treatment at either 400 mg capsules or 300 mg tablets; [†] AEs graded according to NCI CTCAE v5.0; ^{††} No Grade 5 TRAE were reported; [§] Grade 3 TRAEs reported: esophagitis, lymphocyte count decreased, leukopenia; [‡] From starting dose; AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; RP1bD, Recommended Phase 1b Dose; TRAE, treatment-related adverse event; Data cutoff date: 30 September 2024

STRATEGIST 1: Conclusions

- IDRX-42 has demonstrated:
 - Promising responses in previously-treated GIST
 - 2nd line ORR = 53%
 - ≥3rd line ORR = 24%
 - Responses across important *KIT* activating and resistance mutation subsets
 - Durable clinical activity: 9.2 months median PFS in ≥3rd line patients overall
 - Longer median PFS estimated for 3rd line patients overall (12.9 months) and ≥4th line patients without prior ripretinib, at the recommended Phase 1b dose (11.0 months)
 - A favorable safety profile, with manageable AEs
- Phase 1b is ongoing in 1st, 2nd and later-line GIST
 - 1st line cohort remains open to accrual
- A randomized Phase 3 study comparing IDRX-42 to sunitinib in 2nd line GIST is planned

Acknowledgments

The authors would like to thank the patients who are participating in this study, their families and caregivers, as well as the investigators and study teams at all StrateGIST 1 clinical sites.

StrateGIST 1 Countries:

- USA
- Belgium
- France
- Germany
- Spain
- Italy
- Netherlands
- United Kingdom
- Korea
- China

